share_log

Intelligent Bio Solutions | 8-K: Intelligent Bio Solutions Announces Preliminary Unaudited Fiscal 2025 First Quarter Revenue Results

Intelligent Bio Solutions | 8-K: Intelligent Bio Solutions Announces Preliminary Unaudited Fiscal 2025 First Quarter Revenue Results

Intelligent Bio Solutions | 8-K:智能生物解決方案公佈2025財年第一季度未經審計的初步收入業績
美股SEC公告 ·  2024/10/30 05:19

Moomoo AI 已提取核心訊息

Intelligent Bio Solutions announced preliminary unaudited revenue of $0.87 million for Q1 FY2025 ended September 30, 2024, showing a 10% YoY and 20% QoQ increase. The company expects cartridge sales for its Intelligent Fingerprinting Drug Screening System to become the primary revenue driver, promising higher profit margins than reader sales.The company has expanded its global presence, particularly in Saudi Arabia, with international sales projected to rise 15% YoY. The drug screening system, comprising a portable platform and single-use cartridges, tests fingerprint sweat for common workplace drugs including opiates, cocaine, methamphetamine, and cannabis.With over 400 active customer accounts, the company is experiencing growing customer loyalty and steady recurring revenue from cartridge sales. The full financial results for Q1 FY2025 are expected to be disclosed in the Form 10-Q filing during the week of November 4, 2024.
Intelligent Bio Solutions announced preliminary unaudited revenue of $0.87 million for Q1 FY2025 ended September 30, 2024, showing a 10% YoY and 20% QoQ increase. The company expects cartridge sales for its Intelligent Fingerprinting Drug Screening System to become the primary revenue driver, promising higher profit margins than reader sales.The company has expanded its global presence, particularly in Saudi Arabia, with international sales projected to rise 15% YoY. The drug screening system, comprising a portable platform and single-use cartridges, tests fingerprint sweat for common workplace drugs including opiates, cocaine, methamphetamine, and cannabis.With over 400 active customer accounts, the company is experiencing growing customer loyalty and steady recurring revenue from cartridge sales. The full financial results for Q1 FY2025 are expected to be disclosed in the Form 10-Q filing during the week of November 4, 2024.
智能生物解決方案公司宣佈,截至2024年9月30日的2025財年第一季度,初步未經審計的營業收入爲87萬美元,同比增長10%,環比增長20%。公司預計其智能指紋藥物篩查系統的卡匣銷售將成爲主要的營業收入驅動因素,承諾比閱讀器銷售帶來更高的利潤率。該公司已擴大其全球業務,尤其是在沙特阿拉伯,預計國際銷售將同比增長15%。該藥物篩查系統包括一個便攜式平台和一次性卡匣,測試指紋汗液中的常見工作場所藥物,包括鴉片類藥物、可卡因、冰毒和大麻股。公司擁有超過400個活躍客戶賬戶,客戶忠誠度不斷提高,並且由於卡匣銷售帶來了穩定的經常性營業收入。預計2025財年第一季度的完整財務業績將在2024年11月4日那一週的10-Q報告中披露。
智能生物解決方案公司宣佈,截至2024年9月30日的2025財年第一季度,初步未經審計的營業收入爲87萬美元,同比增長10%,環比增長20%。公司預計其智能指紋藥物篩查系統的卡匣銷售將成爲主要的營業收入驅動因素,承諾比閱讀器銷售帶來更高的利潤率。該公司已擴大其全球業務,尤其是在沙特阿拉伯,預計國際銷售將同比增長15%。該藥物篩查系統包括一個便攜式平台和一次性卡匣,測試指紋汗液中的常見工作場所藥物,包括鴉片類藥物、可卡因、冰毒和大麻股。公司擁有超過400個活躍客戶賬戶,客戶忠誠度不斷提高,並且由於卡匣銷售帶來了穩定的經常性營業收入。預計2025財年第一季度的完整財務業績將在2024年11月4日那一週的10-Q報告中披露。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息